Ono Pharmaceutical Co. Ltd. has entered its second agreement this year with a Switzerland-based biotech developing novel antibodies, as it bulks up its research effort fired by the success of the checkpoint inhibitor Opdivo (nivolumab), developed in collaboration with partner Bristol-Myers Squibb Co.
Ono Bulks Up MAb R&D With Second Swiss Biotech Deal
Human-derived monoclonal antibodies targeted against neurodegenerative diseases is the subject of a deal between Japan's Ono Pharmaceutical and Zurich-based biotech Neurimmune.
